Themis Medicare joins hand with Nevakar to tap US pharma market

The Mumbai-based pharma company Themis Medicare Ltd has signed an agreement with Nevakar Llc to market its injectable products in the US and other select markets. “Under this agreement, Themis will develop a selected number of innovative, differentiated injectable products that will be further developed, manufactured and commercialised by Nevakar in the US and select global markets,” said Themis in a BSE filing on September 16, 2016.

Nevakar Llc is a New Jersey (USA) based group having expertise in commercialising pharmaceutical products in US as well as global markets for many years.

Themis Medicare focuses on products in the field of finished dosage formulations and active pharmaceuticals ingredients (APIs), especially in the therapeutic segments such as anti-malaria, anti-tuberculosis, pain management, anaesthetics, etc.